Business Wire·Nov 10, 2026, 8:45 AM ET

Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone

LTRN

Publication in the October 2026 issue of Cancer Research Communications establishes the recommended dose for expansion (RDE) of LP-184 (STAR-001) for a planned Phase 1b/2a trial (NCT07431216) in recurrent glioblastoma (GBM).
LP-184 was generally well tolerated in 16 heavily pretreated patients with recurrent GBM enrolled in a Phase 1a study of 63 patients with advanced solid tumors.
The RDE for LP-184 is 0.39 mg/kg administered intravenously on days 1 and 8 of each 21-day cycle.
Preclinical orthotopic GBM models show that three daily doses of spironolactone reduced tumor ERCC3 levels by approximately 80% and doubled LP-184-induced tumor cell death.
Pharmacokinetic modeling projects that combining LP-184 at the RDE with spironolactone will achieve intratumoral concentrations 2- to 3-fold above the levels needed to kill GBM cells.
No objective radiographic responses were observed as single-agent LP-184, but one MGMT-methylated patient remained clinically stable for over 22 months.
Spironolactone bypasses MGMT-mediated resistance by degrading ERCC3, a key protein in the transcription-coupled nucleotide excision repair pathway.
Spironolactone lowers the concentration of LP-184 required to kill GBM cells by 3- to 6-fold in preclinical models.
A PTGR1 expression threshold associated with LP-184 sensitivity was identified, with 75% of tested pretreatment GBM samples exceeding this threshold.
Lantern Pharma plans to initiate the Phase 1b/2a trial sponsored by its subsidiary Starlight Therapeutics to evaluate the safety, pharmacokinetics, and objective response of the LP-184 and spironolactone combination.
The study utilized Lantern's RADR® AI platform to identify the drug combination and predict patient sensitivity based on DNA damage repair deficiencies.